Shizuoka, Japan

Himoru Kondo

This inventor holds 1 USPTO granted patent. Top assignee: Astellas Pharma Gmbh. Active years: 2011.


Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Himoru Kondo

Introduction

Himoru Kondo is a notable inventor based in Shizuoka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in improving drug absorption. His work has led to the development of innovative solutions that enhance the effectiveness of oral medications.

Latest Patents

Himoru Kondo holds a patent for a pharmaceutical composition for oral use with improved absorption. This invention comprises a drug, aminoalkyl methacrylate copolymer E, and an acidic substance. The composition is created by uniformly mixing these three components, which results in enhanced oral absorption. Additionally, Kondo's invention includes an agent that increases drug permeability of the digestive tract mucous membrane, thereby improving the overall effectiveness of oral medications.

Career Highlights

Kondo is associated with Astellas Pharma GmbH, where he has been instrumental in advancing pharmaceutical research. His innovative approach to drug formulation has garnered attention in the industry, showcasing his commitment to improving patient outcomes through better medication delivery.

Collaborations

Himoru Kondo has collaborated with notable colleagues such as Shunsuke Watanabe and Shigeo Takemura. These partnerships have contributed to the successful development of his patented technologies and have fostered a collaborative environment for innovation.

Conclusion

Himoru Kondo's contributions to pharmaceutical science exemplify the importance of innovation in improving drug delivery systems. His work continues to influence the field, paving the way for advancements that enhance patient care.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…